KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Amortization - Intangibles (2017 - 2025)

Biomarin Pharmaceutical's Amortization - Intangibles history spans 16 years, with the latest figure at $4.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Amortization - Intangibles fell 49.79% year-over-year to $4.8 million, compared with a TTM value of $19.4 million through Dec 2025, down 55.18%, and an annual FY2025 reading of $19.4 million, down 55.18% over the prior year.
  • Amortization - Intangibles for Q4 2025 was $4.8 million at Biomarin Pharmaceutical, roughly flat from $4.8 million in the prior quarter.
  • The five-year high for Amortization - Intangibles was $17.7 million in Q1 2021, with the low at $4.8 million in Q2 2025.
  • Average Amortization - Intangibles over 5 years is $13.1 million, with a median of $15.6 million recorded in 2023.
  • Year-over-year, Amortization - Intangibles rose 18.64% in 2021 and then plummeted 68.06% in 2024.
  • Tracing BMRN's Amortization - Intangibles over 5 years: stood at $17.3 million in 2021, then dropped by 5.94% to $16.3 million in 2022, then decreased by 6.29% to $15.2 million in 2023, then tumbled by 36.66% to $9.7 million in 2024, then tumbled by 49.79% to $4.8 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Amortization - Intangibles are $4.8 million (Q4 2025), $4.8 million (Q3 2025), and $4.8 million (Q2 2025).